Technical Analysis for QNCX - Quince Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Spinning Top | Other | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Parabolic Rise | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
New 52 Week Closing High | Bullish | -4.94% | |
180 Bullish Setup | Bullish Swing Setup | -4.94% | |
Pocket Pivot | Bullish Swing Setup | -4.94% |
Alert | Time |
---|---|
Reversed from Down | about 22 hours ago |
Down 10% | about 23 hours ago |
Down 1 ATR | about 23 hours ago |
Bullish 180 Entry | about 23 hours ago |
Rose Above Previous Day's High | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/12/2024
Quince Therapeutics, Inc. Description
Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Organ Systems Bone Rare Diseases Acute Pain Skeletal Disorders Bone Fracture Skeletal System Musculoskeletal System Osteogenesis Imperfecta
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.79 |
52 Week Low | 0.5116 |
Average Volume | 557,247 |
200-Day Moving Average | 0.93 |
50-Day Moving Average | 0.82 |
20-Day Moving Average | 0.95 |
10-Day Moving Average | 1.14 |
Average True Range | 0.18 |
RSI (14) | 74.62 |
ADX | 64.01 |
+DI | 41.94 |
-DI | 1.09 |
Chandelier Exit (Long, 3 ATRs) | 1.24 |
Chandelier Exit (Short, 3 ATRs) | 1.24 |
Upper Bollinger Bands | 1.50 |
Lower Bollinger Band | 0.40 |
Percent B (%b) | 1.04 |
BandWidth | 114.91 |
MACD Line | 0.17 |
MACD Signal Line | 0.10 |
MACD Histogram | 0.0759 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.99 | ||||
Resistance 3 (R3) | 2.00 | 1.86 | 1.92 | ||
Resistance 2 (R2) | 1.86 | 1.75 | 1.86 | 1.89 | |
Resistance 1 (R1) | 1.70 | 1.67 | 1.63 | 1.69 | 1.86 |
Pivot Point | 1.56 | 1.56 | 1.53 | 1.56 | 1.56 |
Support 1 (S1) | 1.40 | 1.45 | 1.33 | 1.39 | 1.22 |
Support 2 (S2) | 1.26 | 1.37 | 1.26 | 1.19 | |
Support 3 (S3) | 1.10 | 1.26 | 1.17 | ||
Support 4 (S4) | 1.09 |